Optimizing pharmacotherapy to maximize outcome in schizophrenia.

122 J Clin Psychiatry 66:1, January 2005 The Evolution of Antipsychotic Agents: A Mechanisms-Based Review his ACADEMIC HIGHLIGHTS section of The Journal of Clinical Psychiatry presents the highlights of the teleconference “Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia,” held July 13, 2004. This report was prepared by Fusion Medical Education LLC and was supported by an unrestricted educational grant from Bristol-Myers Squibb. The guest editor is John M. Kane, M.D., Department of Psychiatry, Neurology, and Neuroscience, Albert Einstein College of Medicine, Bronx, N.Y. The faculty are Anissa Abi-Dargham, M.D., Department of Psychiatry, Columbia University, New York, N.Y. ; Stephen R. Marder, M.D., Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine at UCLA and UCLA Neuropsychiatric Institute, Los Angeles, Calif. ; Peter J. Weiden, M.D., Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn; Rajiv Tandon, M.D., Chief of Psychiatry, Florida Department of Children and Families, Tallahassee; and Henry A. Nasrallah, M.D., Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center, Cincinnati, Ohio. Faculty Disclosure: In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Kane is a consultant for Abbott, Pfizer, Johnson & Johnson, Eli Lilly, and Janssen and is a member of the speakers/advisory boards for Bristol-Myers Squibb, AstraZeneca, Lundbeck, Novartis, and Janssen. Dr. Abi-Dargham has received grant/ research support from Bristol-Myers Squibb and Eli Lilly; has received honoraria from Abbott; and is a member of the speakers/advisory boards for SanofiSynthelabo, Bristol-Myers Squibb, and Otsuka. Dr. Marder is a consultant for Eli Lilly, Janssen, BristolMyers Squibb, Otsuka, Sanofi-Synthelabo, Lundbeck, Solvay, and Aventis; has received grant/research support from Eli Lilly and Janssen; has received honoraria from Bristol-Myers Squibb and Otsuka; and is a member of the speakers/advisory boards for Bristol-Myers Squibb, Otsuka, Eli Lilly, Janssen, AstraZeneca, Lundbeck, and Solvay. Dr. Weiden has a family member formerly employed by Pfizer; is a consultant for AstraZeneca, Bristol-Myers Squibb, Janssen, Organon, and Pfizer; and has received grant/research support and honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, and Pfizer. Dr. Tandon is a consultant and a member of the speakers/advisory boards for AstraZeneca, Abbott, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer. Dr. Nasrallah is a consultant and a member of the speakers/advisory boards for and has received honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb, Janssen, and Pfizer; and has received grant/research support from AstraZeneca, Forest, Janssen, and Pfizer. The opinions expressed herein are those of the faculty and do not necessarily reflect the views of the program provider, the CME provider and publisher, or the commercial supporter. Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia